

An Indian SME working on developing agentic AI workflow systems to accelerate drug discovery and development is seeking potential European partners for technology, R&D, academic and business collaborations

Summary

Profile type	Company's country	POD reference
Technology offer	India	TOIN20250829008
Profile status	Type of partnership	Targeted countries
PUBLISHED	Commercial agreement with technical assistance	• World
Contact Person	Term of validity	Last update
<u>Enrico FRANZIN</u>	29 Aug 2025 29 Aug 2026	29 Aug 2025

General Information

Short summary

The Indian Company, having its proprietary software applies cutting edge technologies like AI, Deep Learning Networks and Machine Learning algorithms using data driven approaches to re-design the conventional drug design practices involving small molecules, peptides and proteins. With the client's robust discovery and product pipeline, research can be accelerated using latest technology and data driven approaches.

Full description

The India-based AI-driven research company is specializing in developing agentic workflow systems to accelerate drug discovery and development. Their platform integrates autonomous decision-making with molecular design and simulation pipelines, enabling more adaptive and efficient R&D outcomes. At this stage, their GTM product involves a discovery phase platform that comes with three software involving de novo protein design, de novo small molecule design and custom synthesis planning. The three software can either be used in isolation or in tandem using an agentic approach to ensure best hit in your drug discovery pipeline. Additionally, their Clinbolt platform optimizes protocols for clinical trials. They have got an impressive clientele in their portfolio including Dr. Morepen, GSK, L'oreal, Infosys, Indian Institute of Science (IISc), Johns Hopkins University and Buck Institute to name a few.

Advantages and innovations

Boltchem: A software module within the integrated Client's Discovery Suite, powered by Agentic AI and available as a cloud-enabled solution with robust data security protocols or via on-premise deployment at client locations. It enables multi-objective lead optimization, chemical space exploration for molecule design, and AI-driven idea and workflow generation, helping pharma, biotech, and chemical R&D teams rapidly design, evaluate, and optimize small molecules.

Boltpro: A software module within the integrated Client's Discovery Suite, powered by Agentic AI and available both as a cloud-enabled solution, with comprehensive data security protocols, or as an on-premise deployment at client sites. It serves as an advanced AI-driven platform for protein engineering, enabling research teams to smoothly manage end-to-end project workflows, automate tasks, and integrate diverse datasets seamlessly. By doing so, BoltPro streamlines collaboration, enhances real-time progress tracking, and promotes more informed decision-making across the drug discovery and development pipeline in pharma, biotech, and chemical industries.

ReBolt: A software module within the integrated client's Discovery Suite, powered by Agentic AI and offered both as a cloud-enabled solution with strong data security protocols and an on-premise deployment for client environments. It serves as an AI-based synthesis planning tool, designed to streamline reaction pathway design and optimize R&D workflows for drug discovery teams. Built to enhance efficiency in chemical development, ReBolt complements other modules in the suite, such as BoltChem for design and BoltPro for protein engineering, providing a cohesive, intelligent platform across all phases of discovery.

Clinbolt: A software module within the integrated client's Discovery Suite, powered by Agentic AI and available either as a cloud-enabled solution with robust data-security protocols or as an on-premise deployment at client sites. It simplifies c

Technical specification or expertise sought

Stage of development

Already on the market

IPR Status

IPR granted

IPR Notes

They have a proprietary software which is in use in the market.

Sustainable Development goals

• Goal 3: Good Health and Well-being

Partner Sought

Expected role of the partner

The Indian partner is looking for technological, R&D and academic collaborations with the partner in EU. They are

looking for innovation agencies and incubation hubs that in turn has a cohort of companies, AI-Driven pharma companies and Big Technology corporations which can use their product. In terms of academic collaborations, the Indian partner is planning to collaborate with research universities in EU to give customized training programs to the students planning to augment their career in AI and Drug Discovery where the client will serve as the industrial partner.

Type of partnership

Commercial agreement with technical assistance

Type and size of the partner

- **SME 11-49**
- **Other**
- **SME 50 - 249**
- **Big company**

Dissemination

Technology keywords

- **03004007 - Pharmaceuticals**
- **06001002 - Clinical Research, Trials**
- **06001015 - Pharmaceutical Products / Drugs**
- **01003003 - Artificial Intelligence (AI)**

Market keywords

- **05003005 - Drug delivery and other equipment**
- **02007021 - Other Artificial intelligence related**
- **05007002 - Pharmaceuticals/fine chemicals**
- **02007016 - Artificial intelligence related software**

Targeted countries

- **World**

Sector groups involved